However, an easily identifiable surrogate marker of K19+ HCC‐CSCs that can be evaluated in blood samples is still lacking, and this has prevented us from fully predicting patient outcomes or evaluating therapeutic efficacies in HCC patients. Here, KRT19 is linked to hepatocellular carcinoma.